An Overview of Possible Beneficial Effects of Black Seeds (Nigella Sativa) on the Management of "Disease X".

Disease X black seeds kalonji nigella sativa pathogen X thymoquinone

Journal

Infectious disorders drug targets
ISSN: 2212-3989
Titre abrégé: Infect Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269158

Informations de publication

Date de publication:
20 Sep 2024
Historique:
received: 20 02 2024
revised: 28 06 2024
accepted: 15 07 2024
medline: 24 9 2024
pubmed: 24 9 2024
entrez: 24 9 2024
Statut: aheadofprint

Résumé

A mystery pathogen that has not yet infected the entire world's population is predicted to be the cause of Disease X, which will be contagious. According to WHO scientists, 50 million people are expected to die from Disease X, which would be 20 times deadlier than coronavirus disease 2019 (COVID-19). Many international initiatives are currently in motion to get ready for future pandemics. These include updating the International Health Regulation and the European Legislation, establishing the Health Emergency Preparedness and Response Authority (HERA), establishing international hubs, taking on the international challenge of developing a vaccine for Disease X within 100 days of recognition of emerging Pathogen X, and updating the prepared-ness plan of National Institute of Allergy and Infectious Diseases. Our current review's main objective is to determine whether black seeds (Nigella sativa) can manage Disease X. It has been established by several studies that black seeds (N. sativa) have antiviral, antibacterial, antimicro-bial, immunomodulatory, anti-inflammatory, and antioxidant properties, which would be useful in the management of Disease X. Black seeds (N. sativa) may be utilized in conjunction with supportive care and symptomatic therapy to manage Disease X in early phases. Future random-ized controlled clinical trials would further evaluate the safety and effectiveness of black seeds (N. sativa) in patients with Disease X.

Identifiants

pubmed: 39313886
pii: IDDT-EPUB-143203
doi: 10.2174/0118715265304758240821113606
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Naina Mohamed Pakkir Maideen (NMP)

Dubai Health Authority Clinical Pharmacy Dubai United Arab Emirates.

Rajkapoor Balasubramanian (R)

J.K.K. Nattraja College of Pharmacy Pharmacology Komarapalayam India.

Classifications MeSH